Enovis (ENOV) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.88
- Estimate
- $0.77
- Surprise
- +14.8%
- Revenue (period 2026-10-02)
- $558.7M
- Score today
- 6.3/10
Revenue source: xbrl.
How the report landed
Enovis (ENOV) beat the $0.77 estimate with adjusted EPS of $0.88 — a large 14.8% upside surprise.
Where TrendMatrix's rating stands now
TrendMatrix currently rates ENOV Buy (Wait) at 6.3/10; no pre/post engine snapshot brackets this report.
4 of the last 4 quarters beat the estimate; this quarter's +14.8% surprise compares with a +11.0% four-quarter average.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Strong earnings beat streak (4/4)
What argues against it
- V7 low-quality RISK_OFF penalty: -0.5 (Q=4.1)
- Elevated risk factors
- News modifier +2: HOLD_IF_HOLDING → STRONG_BUY_WAIT
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $27.52
- Entry target
- $26.16
- Price target
- $31.39
- Stop
- $24.33
- Upside to target
- +14.1%
- Reward-to-risk
- 0.9:1
Risk check: RSI 73 — a level conventionally read as overbought; gains at these levels often lean on momentum.
Model outputs from TrendMatrix’s engine as of 2026-11-06 — shown for context, not personalized investment advice.
ENOV at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Devices
- Market cap
- $1.65B
- P/E (fwd)
- 8.1
- 52-week range
- $16.70–$32.41
- Off 52-week high
- 15.1%
- RSI (14)
- 73
- Volume vs avg
- 0.18×
- Score today
- 6.3/10